China, U.S. Agree On Ensuring Defective Drugs Not Sent to U.S. (China)
This article was originally published in PharmAsia News
Executive SummaryU.S. and Chinese drug authorities reached an agreement at a summit meeting on safety issues designed to ensure China will not export defective food or drugs to the United States. The drug and medical equipment agreement also requires U.S. authorities to notify Chinese counterparts of recalls, warning letters and reports on adverse side effects. The two sides also agreed to joint investigations by their respective FDAs of suspected companies when defective products are discovered. Implementation details are to be worked out over the next four months. (Click here for more ) "Pact On Drugs, Equipment Safety Inked" China Daily (12/13/07)
You may also be interested in...
After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.